TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2275351

Group type: EXPERIMENTAL
Intervention: Follow-up group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-section sample
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up group (boys only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-section sample (boys only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up group (girls)
Number of subjects: 0
Study: 6893819

Group type: EXPERIMENTAL
Intervention: 30 mg pirenzepine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 20 mg pirenzepine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 0.5 mg atropine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 1 mg atropine
Number of subjects: 43
Study: 29777332

Group type: EXPERIMENTAL
Intervention: 50 Hz tetanic stimulus (S group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No tetanic stimulus (C group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 28359431

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention based on the McGill Model of Nursing
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study: 25495878

Group type: EXPERIMENTAL
Intervention: Ferric citrate (FC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (AC)
Number of subjects: 0
Study: 22519696

Group type: EXPERIMENTAL
Intervention: Motivational intervention (personalized cardiovascular disease risk information) + QBE manipulation (completing a questionnaire about diet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivational intervention (personalized cardiovascular disease risk information)
Number of subjects: 0

Group type: COMPARATOR
Intervention: QBE intervention (completing a questionnaire about diet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 0
Study: 21587091

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI) hysteroscopy
Number of subjects: 801

Group type: COMPARATOR
Intervention: White light (WL) hysteroscopy
Number of subjects: 801
Study: 18788415

Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers
Number of subjects: 0
Study: 16931462

Group type: EXPERIMENTAL
Intervention: Problem-solving coping (women)
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Avoidant coping (men)
Number of subjects: 1287
Study: 12757528

Group type: EXPERIMENTAL
Intervention: RBCs without buffy coat (PC)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: WBC-reduced RBCs filtered before storage (FF)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: WBC-reduced RBCs filtered after storage (SF)
Number of subjects: 404
Study: 10672842

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg given 2 hours before ERCP
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 9419072

Group type: EXPERIMENTAL
Intervention: Normal subjects with active righting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects with passive righting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Labyrinthine-defective (LD) subjects with active righting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Labyrinthine-defective (LD) subjects with passive righting
Number of subjects: 0
Study: 1603291

Group type: EXPERIMENTAL
Intervention: Oxiracetam 800 mg b.i.d. for 90 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxiracetam 800 mg b.i.d. for 1 year (open follow-up)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxiracetam 800 mg b.i.d. during late follow-up
Number of subjects: 60
Study: 3885675

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31622740

Group type: EXPERIMENTAL
Intervention: PENFS
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 50
Study: 29382675

Group type: EXPERIMENTAL
Intervention: Internet-delivered computerised cognitive-behavioural therapy (ICBT) as an adjunct to usual care (UC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 30
Study: 25893719

Group type: EXPERIMENTAL
Intervention: 568 ml (1 pint) water preload
Number of subjects: 14

Group type: COMPARATOR
Intervention: No preload (control trial)
Number of subjects: 14
Study: 24975782

Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation (CCM)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Sham treatment or usual care (Control)
Number of subjects: 641
Study: 22883445

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate, 100 mg epidurally before anesthesia induction and 500 mg added to the infusion postoperatively
Number of subjects: 144

Group type: COMPARATOR
Intervention: Normal saline, 5 mL epidurally before anesthesia induction
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both groups reported severity of pain as 1.0 (1-2) for patients with CPOP
Number of subjects: 144
Study: 20567177

Group type: EXPERIMENTAL
Intervention: Oral misoprostol every 4 hours, up to four doses
Number of subjects: 156

Group type: COMPARATOR
Intervention: Oral misoprostol with isosorbide mononitrate every 6 hours, up to two doses
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Oral misoprostol with isosorbide mononitrate
Number of subjects: 156
Study: 18554954

Group type: EXPERIMENTAL
Intervention: Radix‐Anchor titanium posts
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carbon fiber posts
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glass fiber posts
Number of subjects: 30
Study: 15741421

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet/lifestyle counseling plus immediate fluvastatin 80 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet/lifestyle counseling only, with initiation of fluvastatin 80 mg/day following occurrence of future nonfatal MACE
Number of subjects: 0
Study: 12855211

Group type: EXPERIMENTAL
Intervention: Enhanced gender- and culturally specific HIV intervention
Number of subjects: 333

Group type: COMPARATOR
Intervention: NIDA standard condition
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Crack smoking only group
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: IDU only group
Number of subjects: 333
Study: 10232418

Group type: EXPERIMENTAL
Intervention: SK+early OP (early surgical drainage with adjunctive intrapleural fibrinolysis)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Drain (simple chest tube drainage)
Number of subjects: 82

Group type: COMPARATOR
Intervention: IP-SK (adjunctive intrapleural streptokinase)
Number of subjects: 82
Study: 8914031

Group type: EXPERIMENTAL
Intervention: ACE inhibitor, lisinopril (N = 18)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nondihydropyridine calcium channel blockers (NDCCBs), verapamil SR (N = 8) or diltiazem SR (N = 10)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Beta blocker, atenolol (N = 16)
Number of subjects: 52
Study: 1812908

Group type: EXPERIMENTAL
Intervention: Peroxyl mouthrinse plus chlorhexidine mouthrinse
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo mouthrinse plus chlorhexidine mouthrinse
Number of subjects: 119
Study: 6195026

Group type: EXPERIMENTAL
Intervention: Dermovate ointment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Betnovate ointment (betamethasone valerate 0.1%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propaderm Forte cream (beclomethasone dipropionate 0.5%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propaderm ointment (beclomethasone dipropionate 0.025%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nerisone Forte ointment (diflucortolone valerate 0.3%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nerisone ointment (diflucortolone valerate 0.1%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Adcortyl ointment (triamcinolone acetonide 0.1%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ledercort ointment (triamcinolone acetonide 0.1%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Extemporaneous dilutions of Adcortyl and Ledercort ointments (triamcinolone acetonide 0.025%)
Number of subjects: 10
Study: 31608424

Group type: EXPERIMENTAL
Intervention: Perturbation training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Balance training
Number of subjects: 60

Group type: COMPARATOR
Intervention: No training
Number of subjects: 60
Study: 31428863

Group type: EXPERIMENTAL
Intervention: Controlled hypotension without tourniquet (group H)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Tourniquet use (group T)
Number of subjects: 122
Study: 28973516

Group type: EXPERIMENTAL
Intervention: CONNECT + FALLS
Number of subjects: 1794

Group type: COMPARATOR
Intervention: FALLS only
Number of subjects: 1794
Study: 27599328

Group type: EXPERIMENTAL
Intervention: Bevacizumab nasal spray 25 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bevacizumab nasal spray 50 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bevacizumab nasal spray 75 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24090228

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 22973168

Group type: EXPERIMENTAL
Intervention: Epley maneuver (Ep)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Sémont‐Toupet maneuver (ST)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Postmaneuver restrictions
Number of subjects: 226
Study: 19228089

Group type: EXPERIMENTAL
Intervention: Cone-beam volumetric tomography (CBVT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intraoral radiographs (IRs)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CBVT
Number of subjects: 35

Group type: COMPARATOR
Intervention: CBVT and surgical measurements
Number of subjects: 35
Study: 17288658

Group type: EXPERIMENTAL
Intervention: Videoconferencing assessment by speech-language pathologists (SLPs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Face-to-face assessment by speech-language pathologists (SLPs)
Number of subjects: 24
Study: 15890740

Group type: COMPARATOR
Intervention: 5000 IU hCG (group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200 microg intranasal buserelin followed by 100 microg every 3 days (group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 microg intranasal buserelin followed by 100 microg every 2 days (group C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 microg intranasal buserelin followed by 100 microg every day (group D)
Number of subjects: 24
Study: 12236274

Group type: EXPERIMENTAL
Intervention: Home-based health check with influenza vaccination offer (n = 680, 74.3% uptake)
Number of subjects: 2052

Group type: COMPARATOR
Intervention: Personal letter invitation to attend vaccination clinic (n = 1,372, 67.9% uptake)
Number of subjects: 2052
Study: 9793597

Group type: EXPERIMENTAL
Intervention: Glimepiride (1-8 mg once daily)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study: 8059694

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 317

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 317
Study: 3381638

Group type: EXPERIMENTAL
Intervention: Iodinated salt (20 mg of iodine as iodate/kg salt consumed, assumed consumption of 5 g salt per day)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Non-iodinated salt
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Iodinated salt
Number of subjects: 334
Study: 29615134

Group type: EXPERIMENTAL
Intervention: Structured debriefings and point-of-care bedside practice emphasizing physiologic resuscitation targets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard CPR training)
Number of subjects: 0
Study: 28968232

Group type: EXPERIMENTAL
Intervention: Kinesio® taping
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo tape
Number of subjects: 60

Group type: COMPARATOR
Intervention: No taping (control group)
Number of subjects: 60
Study: 26500320

Group type: EXPERIMENTAL
Intervention: Falls Management Exercise programme (FaME)
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (OEP)
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: FaME
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: FaME and OEP
Number of subjects: 1256
Study: 23254223

Group type: COMPARATOR
Intervention: $10 pre-incentive only
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: $2 pre-incentive and $10 promised incentive
Number of subjects: 3000
Study: 21605278

Group type: EXPERIMENTAL
Intervention: Iodopovidone (20mL of a 10% solution)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Cosmetic talc (5g)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Iodopovidone and Cosmetic talc
Number of subjects: 73
Study: 16570572

Group type: EXPERIMENTAL
Intervention: Emergency endoscopic variceal ligation
Number of subjects: 125

Group type: COMPARATOR
Intervention: Somatostatin (250 microg bolus plus infusion at 250 microg/hour for 48 hours)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Somatostatin
Number of subjects: 125
Study: 12642266

Group type: EXPERIMENTAL
Intervention: Anatomic fixation group (bone plug grafted into tibial tunnel)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonanatomic fixation group (traditional single-incision reconstruction)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All-inside anatomic fixation group
Number of subjects: 60
Study: 11319710

Group type: EXPERIMENTAL
Intervention: Tofu meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lean meat meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Meat meal with added animal fat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High animal fat meal
Number of subjects: 15
Study: 9509965

Group type: EXPERIMENTAL
Intervention: i.o. + i.v. (n = 10)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: i.o. (n = 8)
Number of subjects: 38

Group type: COMPARATOR
Intervention: i.v. (n = 20)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: i.o.
Number of subjects: 38

Group type: COMPARATOR
Intervention: i.v.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: i.o. + i.v., i.o., i.v.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: i.o. and i.v.
Number of subjects: 38
Study: 7914470

Group type: EXPERIMENTAL
Intervention: 135 mg/m2 administered as a single dose over 1 hour
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 135 mg/m2 administered in divided daily doses for 3 days, each over 1 hour
Number of subjects: 56
Study: 3174314

Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin (n = 99)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Saline-vehicle placebo (n = 100)
Number of subjects: 199
Study: 30063273

Group type: EXPERIMENTAL
Intervention: Few LDWs
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Moderate LDWs
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Many LDWs
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Low-risk gamblers
Number of subjects: 132
Study: 27506677

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Aphasia Therapy (CIAT) for 3 hours per day (10 workdays, total 30 hours)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional communication treatment with same intensity without constraints
Number of subjects: 60

Group type: COMPARATOR
Intervention: Individual therapy twice a day plus group therapy (total 14 hours)
Number of subjects: 60
Study: 25976708

Group type: EXPERIMENTAL
Intervention: Fast-setting polyvinyl siloxane (PVS) impression material with heavy body/light body (HB/LB) combination (Imprint 4; 3M ESPE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional PVS impression material with HB/LB combination (Imprint 3; 3M ESPE)
Number of subjects: 20
Study: 23835684

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 68
Study: 21791325

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (transfuse when hematocrit <30% to maintain 30% to 33%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conservative transfusion strategy (transfuse when hematocrit <24% to maintain 24% to 27%)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conservative transfusion strategy
Number of subjects: 45
Study: 19453318

Group type: EXPERIMENTAL
Intervention: Ultrasound guided nerve block
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nerve stimulation
Number of subjects: 44
Study: 16682573

Group type: EXPERIMENTAL
Intervention: Interim telephone model (IT)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Anticoagulation management service (AMS)
Number of subjects: 192
Study: 14731059

Group type: EXPERIMENTAL
Intervention: Zotepine (Nipolept) [12.5-150 mg/day]
Number of subjects: 24
Study: 11736772

Group type: EXPERIMENTAL
Intervention: Esmolol infusion (0-300 microg x kg(‐1) x min(‐1))
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no esmolol infusion)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 68
Study: 9496288

Group type: EXPERIMENTAL
Intervention: Unblinded RCTs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard RCTs
Number of subjects: 0
Study: 8498768

Group type: EXPERIMENTAL
Intervention: History of blood transfusion
Number of subjects: 37337

Group type: COMPARATOR
Intervention: No blood transfusion
Number of subjects: 37337
Study: 31255988

Group type: EXPERIMENTAL
Intervention: Task-oriented training at 100% intensity (n=7)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Task-oriented training at 50% intensity (n=8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional occupational therapy (n=5)
Number of subjects: 20
Study: 29465201

Group type: EXPERIMENTAL
Intervention: esCCO (Estimated continuous cardiac output)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: esCCO
Number of subjects: 23
Study: 26817175

Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate 20 mg/day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate plus Folate 5 mg/day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Folate 5 mg/day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 68
Study: 23398530

Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Empagliflozin (all doses)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 408
Study: 21470815

Group type: COMPARATOR
Intervention: CoCr‐EES
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: PtCr‐EES
Number of subjects: 1530
Study: 18975504

Group type: EXPERIMENTAL
Intervention: Intramuscular placentrex injection along with two-week conventional therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 100
Study: 16311297

Group type: EXPERIMENTAL
Intervention: ICSI patients
Number of subjects: 2055

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2055
Study: 12846709

Group type: EXPERIMENTAL
Intervention: Dolasetron 0.35 mg.kg‐1
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 11151878

Group type: EXPERIMENTAL
Intervention: 20 mg/kg i.v. azathioprine over 36 h
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40 mg/kg i.v. azathioprine over 36 h
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40 mg/kg i.v. azathioprine as three 8‐h infusions over 3 days
Number of subjects: 9
Study: 9120123

Group type: EXPERIMENTAL
Intervention: Standard CVVHD blood lines and heparin concentration (100 units/ml)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Modified circuit design with heparin delivered in a more dilute volume (10 units/ml)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of both circuit configurations
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pre-heparin APTT
Number of subjects: 26
Study: 1732434

Group type: EXPERIMENTAL
Intervention: Telephone counseling (15-minute structured protocol addressing educational, psychosocial, and practical barriers)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control condition (no telephone counseling)
Number of subjects: 90
Study: 6326927

Group type: EXPERIMENTAL
Intervention: High fluid intake (greater than or equal to 3 1/24 h) with chemotherapeutic regimens
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate to render urine neutral
Number of subjects: 80

Group type: COMPARATOR
Intervention: No sodium bicarbonate supplement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High fluid intake
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Light chain proteinuria
Number of subjects: 80
Study: 31674317

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 30144796

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Remifentanil patient controlled analgesia (PCA)
Number of subjects: 409

Group type: COMPARATOR
Intervention: No pharmacological pain relief
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Fear of childbirth antepartum
Number of subjects: 409
Study: 27497386

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Adenoid hypertrophy group
Number of subjects: 80
Study: 24310049

Group type: EXPERIMENTAL
Intervention: Prescription opioid analgesics (oral)
Number of subjects: 11
Study: 22701017

Group type: EXPERIMENTAL
Intervention: TPTD 20 μg once daily by sc injection
Number of subjects: 58

Group type: COMPARATOR
Intervention: ZOL 5 mg by iv infusion
Number of subjects: 58
Study: 20163073

Group type: EXPERIMENTAL
Intervention: LASIK using the SCHWIND AMARIS excimer laser
Number of subjects: 358